Residency · Residency · Emergency Medicine

Opioid Overdose and the Changing Landscape of Substance Use

Epidemiology

The Opioid Crisis

The United States now sees over 100,000 drug overdose deaths annually, with opioids accounting for approximately 75 percent of them. The crisis has evolved through three waves: prescription opioids dominated from the 1990s through 2010, heroin surged beginning in 2010, and illicitly manufactured synthetic opioids, primarily fentanyl, have dominated since 2013. Fentanyl is now found not only in heroin but also in counterfeit pills, cocaine, and the methamphetamine supply. It is 50 to 100 times more potent than morphine, and carfentanil is 10,000 times more potent.

Xylazine-Adulterated Supply

Xylazine, an alpha-2 adrenergic agonist used as a veterinary sedative, is increasingly found mixed with fentanyl in the illicit drug supply. Critically, xylazine does not respond to naloxone because it is not an opioid. It causes prolonged sedation, bradycardia, hypotension, and severe skin necrosis with non-healing wounds. Management is supportive, with atropine for symptomatic bradycardia and wound care for skin complications.

Clinical Presentation

Classic Opioid Toxidrome

The opioid toxidrome consists of CNS depression ranging from drowsiness to coma, respiratory depression with decreased rate and tidal volume leading to hypoxia, hypercarbia, and ultimately respiratory arrest, and miosis with pinpoint pupils. Miosis may be absent if co-ingestants are involved, if the patient is significantly hypoxic, or with meperidine specifically. Additional findings include decreased bowel sounds, hypotension, bradycardia, and hypothermia.

Fentanyl-Specific Features

Fentanyl has a rapid onset of minutes and a short duration of action, which means patients may require repeated naloxone doses or a continuous infusion. Wooden chest syndrome, a rigidity of the chest wall muscles, can make bag-valve-mask ventilation impossible and is treated with naloxone along with a neuromuscular blocking agent such as succinylcholine or rocuronium. Compared to heroin, fentanyl produces higher rates of complete apnea at the time of presentation.

Complications

Complications of opioid overdose include aspiration pneumonitis and pneumonia, non-cardiogenic pulmonary edema (which can occur even after naloxone reversal), rhabdomyolysis from prolonged immobilization, compartment syndrome, and anoxic brain injury in patients who present with a delay.

Naloxone (Narcan)

Mechanism

Naloxone is a competitive mu-opioid receptor antagonist. Its onset of action is 1 to 2 minutes IV, 3 to 5 minutes IM, and 3 to 5 minutes intranasal. Its duration is 30 to 90 minutes, which is shorter than most opioids and creates a risk of renarcotization as the naloxone wears off before the opioid does.

Dosing Strategy

In known opioid-dependent patients, a titration approach is preferred. Start with 0.04 mg IV and double the dose every 2 to 3 minutes (0.04, 0.08, 0.16, 0.4, 2 mg) until spontaneous respirations are restored. The goal is respiratory drive, not full consciousness. This approach avoids precipitating acute withdrawal, which causes agitation, vomiting with aspiration risk, combative behavior, and patients leaving against medical advice.

For undifferentiated or apneic patients, standard dosing of 0.4 to 2 mg IV, IM, or intranasal can be given, repeated every 2 to 3 minutes as needed. Fentanyl overdose may require 10 or more milligrams of naloxone. The intranasal formulation delivers 4 mg per dose and is FDA-approved for bystander and prehospital use. The intramuscular route uses either a 0.4 mg auto-injector or a drawn-up dose.

Naloxone Infusion

A naloxone infusion is indicated when repeated boluses are needed, as occurs with long-acting opioids like methadone or extended-release formulations. The infusion rate is two-thirds of the effective bolus dose per hour, mixed in D5W. For example, if 0.6 mg was the effective bolus, the infusion rate would be 0.4 mg per hour. Close monitoring and titration to maintain respiratory drive are essential.

Post-Naloxone Observation

When only a short-acting opioid is suspected and a single dose of naloxone was effective, the patient should be observed for 1 to 2 hours to monitor for renarcotization. Long-acting opioids like methadone and extended-release formulations require prolonged observation of 12 to 24 hours or a naloxone infusion. If the patient responded to stimulation alone without needing naloxone, the observation period may be shorter. Safe discharge criteria include at least one hour of observation after the last naloxone dose, normal respiratory rate and SpO2 on room air, GCS of 15, and the ability to ambulate.

Acute Opioid Withdrawal

Naloxone can precipitate acute withdrawal, which manifests as agitation, diaphoresis, nausea, vomiting, diarrhea, piloerection, tachycardia, hypertension, abdominal cramping, yawning, lacrimation, and rhinorrhea. Unlike alcohol or benzodiazepine withdrawal, opioid withdrawal is generally not life-threatening, but it is extremely distressing and can lead to vomiting with aspiration, combative behavior, and patients leaving against medical advice. This is precisely why titrating to respiratory effort rather than full reversal is the preferred approach.

ED-Initiated Buprenorphine

Rationale

ED-initiated buprenorphine is supported by evidence (the D'Onofrio trial, 2015) showing that it doubles engagement in addiction treatment at 30 days compared to referral alone, and it reduces illicit opioid use and mortality. However, its adoption has been inconsistent due to historical X-waiver barriers (now removed), stigma, workflow concerns, and lack of follow-up resources. As of 2023, the X-waiver requirement has been eliminated, and any provider with a DEA license can prescribe buprenorphine.

Buprenorphine Basics

Buprenorphine is a partial mu-opioid agonist with high receptor affinity and a ceiling effect on respiratory depression, making it safer than full agonists like methadone in overdose. It is available as a sublingual formulation (Suboxone, which combines buprenorphine with naloxone) and as an injectable depot (Sublocade).

ED Induction Protocol

The patient must be in moderate opioid withdrawal, with a Clinical Opiate Withdrawal Scale (COWS) score of 8 to 12 or higher. The traditional induction starts with 4 to 8 mg sublingual, with an additional 4 mg in 1 to 2 hours if needed, up to 16 to 24 mg on the first day. The risk of precipitated withdrawal exists because buprenorphine's high receptor affinity displaces full agonists from the receptors. If given too early, before sufficient withdrawal has developed, it can precipitate severe withdrawal symptoms.

Micro-dosing, also called the Bernese method, involves giving low and increasing doses of buprenorphine while the patient continues to use full agonists, eliminating the need to be in withdrawal first. This approach is increasingly used for patients on fentanyl, whose long tissue half-life makes traditional induction particularly difficult because adequate withdrawal may take an extended time to develop.

Discharge Planning

Patients should be prescribed a 3 to 7 day supply of buprenorphine/naloxone with outpatient follow-up arranged with addiction medicine or an opioid treatment program within 72 hours. A naloxone kit should be provided for overdose prevention, along with harm reduction resources and referral to peer support.

Harm Reduction in the ED

Naloxone Distribution

Naloxone (nasal or intramuscular) should be prescribed or provided to all opioid overdose patients and their contacts, with education on recognizing and responding to an overdose. Many states allow pharmacist dispensing without a prescription.

Fentanyl Test Strips

Fentanyl test strips allow users to test their drug supply for fentanyl contamination before use. They are increasingly legal and distributed through public health programs.

Safe Injection Practices

Non-judgmental counseling on risk reduction should be offered, including advice to avoid using alone, to carry naloxone, and to test the drug supply. Wound care should be provided for injection-related complications, and screening for HIV, hepatitis C, and sexually transmitted infections should be performed.

Other Substances of Concern

Methamphetamine

Methamphetamine produces a sympathomimetic toxidrome with agitation, tachycardia, hypertension, hyperthermia, and psychosis. Treatment relies on benzodiazepines (often in high doses), active cooling, and IV fluids. Complications include hemorrhagic stroke, myocardial infarction, rhabdomyolysis, and aortic dissection.

Novel Psychoactive Substances (NPS)

Synthetic cannabinoids (K2, Spice) can cause altered mental status, agitation, seizures, and cardiac toxicity. Synthetic cathinones (bath salts) produce a sympathomimetic toxidrome and can trigger excited delirium. GHB and GBL cause CNS and respiratory depression with rapid onset and rapid recovery but have no specific antidote. Kratom produces opioid-like effects at high doses and stimulant effects at low doses, with seizures reported.

<image>A dosing algorithm infographic for naloxone administration in opioid overdose. Starting with "Patient with suspected opioid overdose — apneic or hypoventilating." If IV access available: start naloxone 0.04 mg IV, with a titration ladder showing dose doubling every 2-3 minutes (0.04 → 0.08 → 0.16 → 0.4 → 2 mg → 4 mg → 10 mg). If no IV access: IM 0.4-2 mg or IN 4 mg. A callout box notes: "Goal = restore spontaneous respirations, NOT full consciousness." Below, a renarcotization timeline shows naloxone's 30-90 minute duration vs. common opioids' longer durations (heroin 3-4 hours, oxycodone 4-6 hours, methadone 24-48 hours), highlighting when re-dosing or infusion may be needed. A red warning box notes: "Fentanyl overdose may require 10+ mg naloxone; wooden chest syndrome may require paralytic."</image>

<image>A flowchart for ED-initiated buprenorphine. Step 1: Identify patient with opioid use disorder in the ED (post-overdose, withdrawal, or self-identified). Step 2: Assess for readiness and interest in treatment. Step 3: Evaluate for withdrawal using the Clinical Opiate Withdrawal Scale (COWS) — score 8-12 or higher indicates moderate withdrawal and readiness for induction. Step 4: Traditional induction — buprenorphine/naloxone 4-8 mg SL, with additional 4 mg q1-2h as needed (max 16-24 mg day 1). Alternative: micro-dosing protocol for patients on fentanyl who cannot achieve sufficient withdrawal. Step 5: Prescribe 3-7 day supply, provide naloxone kit, arrange 72-hour outpatient follow-up. Step 6: Discharge with harm reduction counseling and community resource information.</image>

Clinical Pearls

Naloxone should be titrated to respiratory effort, not full alertness, because over-reversal precipitates withdrawal, agitation, vomiting, and patients leaving against medical advice. Fentanyl overdose may require much higher naloxone doses (10 or more milligrams), and wooden chest syndrome may prevent bag-valve-mask ventilation, necessitating naloxone along with a paralytic agent. Naloxone's duration of 30 to 90 minutes is shorter than most opioids, so patients must be observed for renarcotization, and methadone requires extended observation or an infusion. Xylazine does not respond to naloxone, and its associated bradycardia, hypotension, and skin wounds must be managed supportively. ED-initiated buprenorphine doubles treatment engagement, and the X-waiver is no longer required, meaning all DEA-licensed providers can prescribe it. Micro-dosing buprenorphine avoids precipitated withdrawal and is particularly useful in the fentanyl era. All patients should be sent home with naloxone kits and overdose education, even if they decline addiction treatment. Non-cardiogenic pulmonary edema can occur after opioid overdose reversal, so monitoring should continue even after successful naloxone administration.

References

• D'Onofrio G, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence. JAMA. 2015;313:1636-1644.
• Stolbach A, Hoffman RS. Acute opioid intoxication in adults. UpToDate. 2023.
• Rzasa Lynn R, Galinkin JL. Naloxone dosage for opioid reversal. Addiction. 2018;113:6-17.
• Hämmig R, et al. Use of microdoses for induction of buprenorphine treatment (Bernese method). Subst Abuse Rehabil. 2016;7:99-105.
• Friedman J, et al. Xylazine spreads across the US drug supply. Drug Alcohol Depend. 2022;233:109380.

Read this lecture as Markdown